JOP20200072A1 - طرق علاج سرطان البروستاتا من خلال إعطاء أسيتات الأبيراتيرون إلى جانب البريدنيزون مع المعالجة بحرمان الأندروجين - Google Patents
طرق علاج سرطان البروستاتا من خلال إعطاء أسيتات الأبيراتيرون إلى جانب البريدنيزون مع المعالجة بحرمان الأندروجينInfo
- Publication number
- JOP20200072A1 JOP20200072A1 JOP/2020/0072A JOP20200072A JOP20200072A1 JO P20200072 A1 JOP20200072 A1 JO P20200072A1 JO P20200072 A JOP20200072 A JO P20200072A JO P20200072 A1 JOP20200072 A1 JO P20200072A1
- Authority
- JO
- Jordan
- Prior art keywords
- methods
- prostate cancer
- abiraterone acetate
- treating prostate
- androgen deprivation
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 2
- 229960004103 abiraterone acetate Drugs 0.000 title abstract 2
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 title abstract 2
- 238000009167 androgen deprivation therapy Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 title abstract 2
- 229960004618 prednisone Drugs 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
يتم الإفصاح عن طرق علاج سرطان البروستاتا من خلال إعطاء أسيتات الأبيراتيرون إلى جانب البريدنيزون مع المعالجة بحرمان الأندروجين. الشكل 1A
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762570781P | 2017-10-11 | 2017-10-11 | |
| PCT/US2018/017438 WO2019074536A1 (en) | 2017-10-11 | 2018-02-08 | METHODS OF TREATING PROSTATE CANCER BY ADMINISTERING ABIRATERONE ACETATE AND PREDNISONE WITH ANDROGENIC SEPARATION THERAPY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20200072A1 true JOP20200072A1 (ar) | 2020-04-29 |
Family
ID=61283312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2020/0072A JOP20200072A1 (ar) | 2017-10-11 | 2018-02-08 | طرق علاج سرطان البروستاتا من خلال إعطاء أسيتات الأبيراتيرون إلى جانب البريدنيزون مع المعالجة بحرمان الأندروجين |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20190105332A1 (ar) |
| EP (1) | EP3694604A1 (ar) |
| JP (1) | JP2020536903A (ar) |
| KR (1) | KR20200068689A (ar) |
| CN (1) | CN111542373A (ar) |
| AU (1) | AU2018347804A1 (ar) |
| BR (1) | BR112020007090A2 (ar) |
| CA (1) | CA3077678A1 (ar) |
| EA (1) | EA202090916A1 (ar) |
| IL (1) | IL273826A (ar) |
| JO (1) | JOP20200072A1 (ar) |
| MA (1) | MA50341A (ar) |
| MX (1) | MX2020003830A (ar) |
| PH (1) | PH12020550151A1 (ar) |
| UA (1) | UA124865C2 (ar) |
| WO (1) | WO2019074536A1 (ar) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA124972C2 (uk) | 2016-07-29 | 2021-12-22 | Янссен Фармацевтика Нв | Способи лікування раку передміхурової залози |
| US10702508B2 (en) | 2017-10-16 | 2020-07-07 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
| TWI905184B (zh) * | 2020-05-08 | 2025-11-21 | 比利時商健生藥品公司 | 用醋酸阿比特龍和尼拉帕尼之組合治療前列腺癌 |
| US11957696B2 (en) * | 2021-02-15 | 2024-04-16 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102898495B (zh) * | 2012-11-12 | 2014-11-26 | 浙江神洲药业有限公司 | 醋酸阿比特龙酯的制备方法 |
-
2018
- 2018-02-08 JO JOP/2020/0072A patent/JOP20200072A1/ar unknown
- 2018-02-08 EP EP18707472.9A patent/EP3694604A1/en not_active Withdrawn
- 2018-02-08 AU AU2018347804A patent/AU2018347804A1/en not_active Abandoned
- 2018-02-08 EA EA202090916A patent/EA202090916A1/ru unknown
- 2018-02-08 JP JP2020520290A patent/JP2020536903A/ja active Pending
- 2018-02-08 UA UAA202002743A patent/UA124865C2/uk unknown
- 2018-02-08 MX MX2020003830A patent/MX2020003830A/es unknown
- 2018-02-08 WO PCT/US2018/017438 patent/WO2019074536A1/en not_active Ceased
- 2018-02-08 KR KR1020207012842A patent/KR20200068689A/ko not_active Ceased
- 2018-02-08 MA MA050341A patent/MA50341A/fr unknown
- 2018-02-08 US US15/891,974 patent/US20190105332A1/en not_active Abandoned
- 2018-02-08 CN CN201880079993.2A patent/CN111542373A/zh active Pending
- 2018-02-08 CA CA3077678A patent/CA3077678A1/en active Pending
- 2018-02-08 BR BR112020007090-4A patent/BR112020007090A2/pt not_active IP Right Cessation
-
2019
- 2019-11-05 US US16/674,323 patent/US20200069704A1/en not_active Abandoned
-
2020
- 2020-03-26 PH PH12020550151A patent/PH12020550151A1/en unknown
- 2020-04-06 IL IL273826A patent/IL273826A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA50341A (fr) | 2020-08-19 |
| IL273826A (en) | 2020-05-31 |
| PH12020550151A1 (en) | 2021-02-08 |
| EP3694604A1 (en) | 2020-08-19 |
| EA202090916A1 (ru) | 2020-12-11 |
| BR112020007090A2 (pt) | 2020-09-24 |
| WO2019074536A1 (en) | 2019-04-18 |
| US20190105332A1 (en) | 2019-04-11 |
| CN111542373A (zh) | 2020-08-14 |
| MX2020003830A (es) | 2020-11-06 |
| AU2018347804A1 (en) | 2020-04-16 |
| UA124865C2 (uk) | 2021-12-01 |
| CA3077678A1 (en) | 2019-04-18 |
| KR20200068689A (ko) | 2020-06-15 |
| US20200069704A1 (en) | 2020-03-05 |
| JP2020536903A (ja) | 2020-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20190244A1 (ar) | تركيبة علاجية لسرطان البروستاتا | |
| PH12020550151A1 (en) | Methods of treating prostate cancer | |
| MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
| EP4656246A3 (en) | Combination therapies for the treatment of cancer | |
| MX2018008427A (es) | Combinaciones anti-cd20 para tratar tumores. | |
| MX2015014046A (es) | Combinaciones de farmacos para tratar cancer. | |
| EP4552698A3 (en) | Methods of treating prostate cancer | |
| PH12015502342B1 (en) | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer | |
| PH12017501879A1 (en) | Methods for treating cancer | |
| MX2019008233A (es) | Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral. | |
| TW201613587A (en) | Medical treatments based on anamorelin | |
| MX2016009515A (es) | Metodos para utilizar anticuerpos anti-steap1 e inmunoconjugados. | |
| IL279591A (en) | Cancer treatment methods using combination therapy | |
| JOP20220288A1 (ar) | علاج سرطان البروستات بتوليفة من أبيراتيرون أسيتات ونيراباريب | |
| MX2021002884A (es) | Terapia de combinacion para el tratamiento de cancer de prostata. | |
| MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
| HK40011817A (en) | Methods of diagnosing and treating abiraterone acetate- glucocorticoid -resistant or -sensitive metastatic castration resistant prostate cancer | |
| EA201990411A1 (ru) | Способы лечения рака предстательной железы |